APO Research, Inc.

APO RESEARCH · REPORT

Alectinib

Selected research

Market Outlook & Growth Opportunities

Global Alectinib Market Outlook and Growth Opportunities 2026

Market perspective

The global Alectinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Alectinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Alectinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Alectinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Alectinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Alectinib market include Roche and Everest Pharmaceuticals among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Alectinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alectinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alectinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alectinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Alectinib Segment by Company

Roche

Everest Pharmaceuticals

Alectinib Segment by Type

150mg*140 Capsules

150mg*26 Capsules

150mg*28 Capsules

20mg*1 Capsule

40mg*1 Capsule

Alectinib Segment by Application

Advanced NSCLC

Recurrent NSCLC

Unresectable NSCLC

Others

Alectinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Alectinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Alectinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alectinib significant trends, drivers, influence factors in global and regions.

6. To analyze Alectinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alectinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alectinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alectinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Alectinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alectinib industry.

Chapter 3: Detailed analysis of Alectinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Alectinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Alectinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alectinib Industry Trends Table 2. Alectinib Industry Drivers Table 3. Alectinib Industry Opportunities and Challenges Table 4. Alectinib Industry Restraints Table 5. Global Alectinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alectinib Revenue Share by Company (2021-2026) Table 7. Global Alectinib Sales Volume by Company (k units) & (2021-2026) Table 8. Global Alectinib Sales Volume Share by Company (2021-2026) Table 9. Global Alectinib Average Price (US$/unit) of Company (2021-2026) Table 10. Global Alectinib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Alectinib Key Company Manufacturing Base & Headquarters Table 12. Global Alectinib Company, Product Type & Application Table 13. Global Alectinib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Alectinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 150mg*140 Capsules Table 18. Significant Companies of 150mg*26 Capsules Table 19. Significant Companies of 150mg*28 Capsules Table 20. Significant Companies of 20mg*1 Capsule Table 21. Significant Companies of 40mg*1 Capsule Table 22. Global Alectinib Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Alectinib Sales Volume by Type (2021-2026) & (k units) Table 24. Global Alectinib Sales Volume by Type (2027-2032) & (k units) Table 25. Global Alectinib Sales Volume Share by Type (2021-2026) Table 26. Global Alectinib Sales Volume Share by Type (2027-2032) Table 27. Global Alectinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Alectinib Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Alectinib Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Alectinib Sales Value Share by Type (2021-2026) Table 31. Global Alectinib Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Advanced NSCLC Table 33. Significant Companies of Recurrent NSCLC Table 34. Significant Companies of Unresectable NSCLC Table 35. Significant Companies of Others Table 36. Global Alectinib Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Alectinib Sales Volume by Application (2021-2026) & (k units) Table 38. Global Alectinib Sales Volume by Application (2027-2032) & (k units) Table 39. Global Alectinib Sales Volume Share by Application (2021-2026) Table 40. Global Alectinib Sales Volume Share by Application (2027-2032) Table 41. Global Alectinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Alectinib Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Alectinib Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Alectinib Sales Value Share by Application (2021-2026) Table 45. Global Alectinib Sales Value Share by Application (2027-2032) Table 46. Global Alectinib Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Alectinib Sales by Region (2021-2026) & (k units) Table 48. Global Alectinib Sales Market Share by Region (2021-2026) Table 49. Global Alectinib Sales by Region (2027-2032) & (k units) Table 50. Global Alectinib Sales Market Share by Region (2027-2032) Table 51. Global Alectinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Alectinib Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Alectinib Sales Value Share by Region (2021-2026) Table 54. Global Alectinib Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Alectinib Sales Value Share by Region (2027-2032) Table 56. Global Alectinib Market Average Price (US$/unit) by Region (2021-2026) Table 57. Global Alectinib Market Average Price (US$/unit) by Region (2027-2032) Table 58. Global Alectinib Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Global Alectinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Alectinib Sales by Country (2021-2026) & (k units) Table 61. Global Alectinib Sales Market Share by Country (2021-2026) Table 62. Global Alectinib Sales by Country (2027-2032) & (k units) Table 63. Global Alectinib Sales Market Share by Country (2027-2032) Table 64. Global Alectinib Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Alectinib Sales Value Market Share by Country (2021-2026) Table 66. Global Alectinib Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Alectinib Sales Value Market Share by Country (2027-2032) Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Alectinib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Roche Alectinib Product Portfolio Table 72. Roche Recent Development Table 73. Everest Pharmaceuticals Company Information Table 74. Everest Pharmaceuticals Business Overview Table 75. Everest Pharmaceuticals Alectinib Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Everest Pharmaceuticals Alectinib Product Portfolio Table 77. Everest Pharmaceuticals Recent Development Table 78. Key Raw Materials Table 79. Raw Materials Key Suppliers Table 80. Alectinib Distributors List Table 81. Alectinib Customers List Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Alectinib Product Image Figure 2. Global Alectinib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alectinib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Alectinib Sales (2021-2032) & (k units) Figure 5. Global Alectinib Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Alectinib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 150mg*140 Capsules Image Figure 10. 150mg*26 Capsules Image Figure 11. 150mg*28 Capsules Image Figure 12. 20mg*1 Capsule Image Figure 13. 40mg*1 Capsule Image Figure 14. Global Alectinib Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Alectinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Alectinib Sales Volume Share by Type (2021-2032) Figure 17. Global Alectinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Alectinib Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Alectinib Sales Value Share by Type (2021-2032) Figure 20. Advanced NSCLC Image Figure 21. Recurrent NSCLC Image Figure 22. Unresectable NSCLC Image Figure 23. Others Image Figure 24. Global Alectinib Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Alectinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Alectinib Sales Volume Share by Application (2021-2032) Figure 27. Global Alectinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Alectinib Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Alectinib Sales Value Share by Application (2021-2032) Figure 30. Global Alectinib Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 31. Global Alectinib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Alectinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Alectinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Alectinib Sales Value (2021-2032) & (US$ Million) Figure 35. North America Alectinib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Alectinib Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Alectinib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Alectinib Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Alectinib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Alectinib Sales Value (2021-2032) & (US$ Million) Figure 41. South America Alectinib Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Alectinib Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Alectinib Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Alectinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Alectinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Alectinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Alectinib Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Alectinib Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • 150mg*140 Capsules
  • 150mg*26 Capsules
  • 150mg*28 Capsules
  • 20mg*1 Capsule
  • 40mg*1 Capsule
Applications
  • Advanced NSCLC
  • Recurrent NSCLC
  • Unresectable NSCLC
  • Others
Companies covered
  • Roche
  • Everest Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Alectinib Sales Value (2021-2032)
  4. 1.2.2 Global Alectinib Sales Volume (2021-2032)
  5. 1.2.3 Global Alectinib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Alectinib Market Dynamics
  1. 2.1 Alectinib Industry Trends
  2. 2.2 Alectinib Industry Drivers
  3. 2.3 Alectinib Industry Opportunities and Challenges
  4. 2.4 Alectinib Industry Restraints
3 Alectinib Market by Company
  1. 3.1 Global Alectinib Company Revenue Ranking in 2025
  2. 3.2 Global Alectinib Revenue by Company (2021-2026)
  3. 3.3 Global Alectinib Sales Volume by Company (2021-2026)
  4. 3.4 Global Alectinib Average Price by Company (2021-2026)
  5. 3.5 Global Alectinib Company Ranking (2024-2026)
  6. 3.6 Global Alectinib Company Manufacturing Base and Headquarters
  7. 3.7 Global Alectinib Company Product Type and Application
  8. 3.8 Global Alectinib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Alectinib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Alectinib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Alectinib Market by Type
  1. 4.1 Alectinib Type Introduction
  2. 4.1.1 150mg*140 Capsules
  3. 4.1.2 150mg*26 Capsules
  4. 4.1.3 150mg*28 Capsules
  5. 4.1.4 20mg*1 Capsule
  6. 4.1.5 40mg*1 Capsule
  7. 4.2 Global Alectinib Sales Volume by Type
  8. 4.2.1 Global Alectinib Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Alectinib Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Alectinib Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Alectinib Sales Value by Type
  12. 4.3.1 Global Alectinib Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Alectinib Sales Value by Type (2021-2032)
  14. 4.3.3 Global Alectinib Sales Value Share by Type (2021-2032)
5 Alectinib Market by Application
  1. 5.1 Alectinib Application Introduction
  2. 5.1.1 Advanced NSCLC
  3. 5.1.2 Recurrent NSCLC
  4. 5.1.3 Unresectable NSCLC
  5. 5.1.4 Others
  6. 5.2 Global Alectinib Sales Volume by Application
  7. 5.2.1 Global Alectinib Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Alectinib Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Alectinib Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Alectinib Sales Value by Application
  11. 5.3.1 Global Alectinib Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Alectinib Sales Value by Application (2021-2032)
  13. 5.3.3 Global Alectinib Sales Value Share by Application (2021-2032)
6 Alectinib Regional Sales and Value Analysis
  1. 6.1 Global Alectinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alectinib Sales by Region (2021-2032)
  3. 6.2.1 Global Alectinib Sales by Region: 2021-2026
  4. 6.2.2 Global Alectinib Sales by Region (2027-2032)
  5. 6.3 Global Alectinib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Alectinib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Alectinib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Alectinib Sales Value by Region (2027-2032)
  9. 6.5 Global Alectinib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Alectinib Sales Value (2021-2032)
  12. 6.6.2 North America Alectinib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Alectinib Sales Value (2021-2032)
  15. 6.7.2 Europe Alectinib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Alectinib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Alectinib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Alectinib Sales Value (2021-2032)
  21. 6.9.2 South America Alectinib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Alectinib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Alectinib Sales Value Share by Country, 2025 VS 2032
7 Alectinib Country-level Sales and Value Analysis
  1. 7.1 Global Alectinib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alectinib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Alectinib Sales by Country (2021-2032)
  4. 7.3.1 Global Alectinib Sales by Country (2021-2026)
  5. 7.3.2 Global Alectinib Sales by Country (2027-2032)
  6. 7.4 Global Alectinib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Alectinib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Alectinib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Alectinib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Alectinib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Alectinib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Alectinib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Alectinib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Alectinib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Alectinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Alectinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Alectinib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Alectinib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Alectinib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Alectinib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Alectinib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Alectinib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Alectinib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Alectinib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Alectinib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Alectinib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Alectinib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Alectinib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Alectinib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Alectinib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Alectinib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Alectinib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Alectinib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Alectinib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Alectinib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Alectinib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Alectinib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Alectinib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Alectinib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Alectinib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Alectinib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Alectinib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Alectinib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Alectinib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Alectinib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Alectinib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Alectinib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Alectinib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Alectinib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Alectinib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Alectinib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Alectinib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Alectinib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Alectinib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Alectinib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Alectinib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Alectinib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Alectinib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Alectinib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Alectinib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Alectinib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Alectinib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Alectinib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Alectinib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Alectinib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Alectinib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Alectinib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Alectinib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Alectinib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Alectinib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Alectinib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Alectinib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Alectinib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Alectinib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Alectinib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Alectinib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Alectinib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Alectinib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Alectinib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Alectinib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Alectinib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Alectinib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Alectinib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Alectinib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Alectinib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Alectinib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Alectinib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Alectinib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Alectinib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Alectinib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Alectinib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Alectinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Alectinib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Roche Alectinib Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Everest Pharmaceuticals
  8. 8.2.1 Everest Pharmaceuticals Company Information
  9. 8.2.2 Everest Pharmaceuticals Business Overview
  10. 8.2.3 Everest Pharmaceuticals Alectinib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Everest Pharmaceuticals Alectinib Product Portfolio
  12. 8.2.5 Everest Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Alectinib Value Chain Analysis
  2. 9.1.1 Alectinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Alectinib Sales Mode & Process
  6. 9.2 Alectinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Alectinib Distributors
  9. 9.2.3 Alectinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.